Emerald Health Therapeutics Appoints Robert C. Hill, CPA, CA as Chief Financial Officer and Promotes Cheryl Evans, CPA, CA to...
November 20 2017 - 8:30AM
Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF)
(“Emerald”) today announced the appointment of Robert C. Hill, CPA,
CA, as the Company's Chief Financial Officer and the promotion of
Cheryl L. Evans, CPA, CA, to Vice President Finance. Together Mr.
Hill and Ms. Evans will be responsible for leading Emerald’s
financial operations and organizational functions to facilitate the
significant anticipated expansion of the Company’s business with
the expected legalization of adult use cannabis in Canada by July
2018. Sandy Pratt, CPA, CA, has resigned as Chief Financial Officer
to pursue other opportunities.
“We welcome Rob to Emerald’s executive team. His
experience in strategic planning, financial and operational
management, and building collaborative, high-performing
organizations will help us further advance our mission to be a
leader in the global cannabis industry,” said Chris Wagner, Chief
Executive Officer of Emerald.
“Cheryl has been impactful since starting as
Emerald’s controller earlier this year. We will benefit from her
expertise in internal and external financial reporting, budgeting,
controls and software systems to support our rapid growth. We also
sincerely thank Sandy Pratt for her dedication and valuable
contributions to Emerald’s growth over the past two years.”
Mr. Hill brings over 20 years of accounting,
finance, and senior leadership experience to Emerald as a seasoned
manager of private and publicly traded technology and financial
services businesses in Canada, USA, and Asia. Prior to joining
Emerald, Mr. Hill was the Chief Financial Officer of Tokyo-based
Minkabu, a technology company advancing sophisticated stock market
intelligence and financial data solutions. Before that, he held
financial leadership positions at Haywood Securities in Vancouver,
and Vignette Corp. and Trilogy Software in Austin, Texas.
Mr. Hill earned a Bachelor of Science from the
University of British Columbia and his certification from the
Chartered Professional Accountants of British Columbia, Canada
while articling with KPMG LLP.
Mr. Hill has been granted an option to acquire
up to 250,000 common shares vesting over three years.
Ms. Evans has almost 20 years of management
experience in the accounting, finance and treasury functions of
publicly listed and highly regulated private companies. Prior to
Emerald, she held various roles including Director, Regulatory
Compliance and Director, Finance at AscendantFX Capital Inc, an
international foreign currency payments provider, and VP, Financial
Operations at Partners Real Estate Investment Trust.
Ms. Evans achieved her Bachelor of Commerce in
international business, with distinction, from the University of
Victoria. She articled at Grant Thornton LLP for her CPA, CA
designation, and subsequently worked with publicly listed companies
at KPMG LLP.
Join us on our journey of making lives
better through cannabis science.
About Emerald Health Therapeutics
Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH)
(OTCQX:EMHTF) operates through Emerald Health Botanicals Inc.
("Botanicals"), a wholly owned subsidiary and Licensed Producer
under Canada’s Access to Cannabis for Medical Purposes Regulations.
Botanicals is authorized to produce and sell dried medical cannabis
flower and medical cannabis oil. It currently operates an indoor
facility in Victoria, BC, and is building a 150,000 s.f. hybrid
greenhouse on 32 acres in Metro Vancouver, with the potential to
expand this facility to 1 million s.f. to address the needs of the
legal Canadian recreational cannabis market. Botanicals has also
entered into a partnership with Village Farms to convert an
existing 1.1 million s.f. greenhouse in Delta, BC from growing
tomatoes to growing cannabis. Emerald’s team is highly experienced
in life sciences, product development and large-scale agribusiness.
Emerald and Botanicals are part of the Emerald Health group, which
is broadly focused on developing pharmaceutical, botanical and
nutraceutical products designed to provide wellness and medical
benefits through interacting with the human body’s endocannabinoid
system.
For investor and media
contacts:invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward
Looking Information
Certain statements in this press release
constitute forward-looking statements, within the meaning of
applicable securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking
statements" involve known and unknown risks and uncertainties that
could cause actual and future events to differ materially from
those anticipated in such statements.
Forward-looking statements include, but are not
limited to, statements with respect to expansion of Emerald’s
business; creation of strategic development opportunities;
commercial operations; construction or conversion of
production facilities; international opportunities for the Company;
the Company becoming a leading Canadian supplier of cannabis
products; expected timing of any of the above matters; and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of management.
Emerald Health Therapeutics Inc. does not
intend, and does not assume any obligation, to update these
forward-looking statements except as required by law. These
forward-looking statements involve risks and uncertainties relating
to, among other things, failure to obtain regulatory approval for
closing of the proposed transaction or to meet the conditions set
out in the Agreement; failure of the federal government to approve
legislation legalizing sales of non-therapeutic adult-use cannabis;
failure to obtain Health Canada and other regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; the Company's historical experience with medical
marijuana operations; results of scientific research; uninsured
risks; regulatory changes; difficulties in construction or in
obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company’s annual information form and
other filings with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024